Intelerad and Zebra Medical Vision Join Forces to Accelerate AI Adoption Through Newly Released Intelerad’s Odyssey Workflow Solution and Announce Unparalleled Introductory Offer

Zebra-med’s AI1-Enabled Workflow Excellence to be Within Reach for Healthcare Service Providers of All Sizes

MONTREAL & KIBBUTZ SHEFAYIM, Israel–(BUSINESS WIRE)–#FDAIntelerad Medical Systems™, a leader in enterprise workflow solutions, and Zebra Medical Vision, the deep learning medical imaging analytics company, announce a joint program leveraging Intelerad’s newly released Odyssey designed to encourage the adoption of artificial intelligence without the prohibitive costs usually associated with such programs.

The positive impact of artificial intelligence technology has been demonstrated in many fields, including that of radiology. Indeed, AI can help radiologists increase productivity, improve clinical decisions and, ultimately, provide high quality care when the technology is tightly managed and smartly integrated in the workflow.

Odyssey harnesses the power of artificial intelligence and the technology behind the Intelerad worklist to offer an unparalleled workflow management solution, comprised of the clinical AI engine, powered by Zebra-med’s AI1 ™ “all-in-one” bundle of FDA cleared AI applications. Connected via API, it analyses the images and automatically returns the findings to the worklist which then escalates the study to the radiologist’s attention.

“Odyssey will deliver state-of-the-art clinical AI solutions directly integrated into the radiologists’ natural workflow and tailored to the needs of individual organizations,” said Chris Wood, Chief Technology Officer at Intelerad. “With Zebra-Med’s AI1, we are committed to providing a broad and growing portfolio of high-value, innovative technology solutions to our customers and this unprecedented approach to artificial intelligence in radiology will extend our leadership position in workflow management.”

“We are excited to be supporting Intelerad team and the 300 healthcare organizations they serve, with our “all-in-one” AI1 ever growing portfolio of FDA cleared AI products,“ noted Eyal Gura, CEO of Zebra Medical Vision. “We are committed to bring more AI value in an integrated way to the workflow and in all modalities.”

With Odyssey, Intelerad and Zebra-Med are removing two critical barriers to AI accessibility: the prohibitive cost of AI platforms and the need for demonstrated impact prior to committing resources to AI. Through a pay-per-study model and by eliminating the high, up front flat-fee models typically offered in the market, Intelerad intends to encourage AI adoption by healthcare service providers of all sizes. Therefore, for a limited time, Intelerad will subsidize and secure for its customers 12 months of trial use of the AI1 clinical algorithms.

To sign up or learn more, visit Intelerad at the RANZCR Annual Scientific Meeting, October 17-20 in Auckland, New Zealand, stand 21 or reserve a demonstration at the upcoming RSNA Annual meeting in Chicago, USA by visiting

For more information about Intelerad, please visit

Zebra Medical Vision will be showcasing at RSNA 2019 [booth 10527], to reserve a meeting or a demo please visit

For more information please visit Zebra-Med’s blog.

About Intelerad

Founded in 1999, Intelerad is a medical imaging software provider that specializes in diagnostic viewing, reporting and collaboration solutions. Headquartered in Montreal, Intelerad has 400 employees located in various offices in Toronto and Calgary (CA), Seattle (US), Hertfordshire (UK) and Melbourne (AU). The company serves over 300 healthcare organizations around the world, such as hospitals, radiology groups, imaging centers, clinics and reading groups.

Intelerad’s continued success in the international market was recently acknowledged by a Best in KLAS recognition, ranking #1 for PACS Canada and PACS Asia/Oceania in the 2019 Best in KLAS: Global Software (Non-US) report.

About Zebra Medical Vision

Zebra Medical Vision’s Imaging Analytics Platform allows healthcare institutions to identify patients at risk of disease and offer improved, preventative treatment pathways to improve patient care. Zebra-Med was founded in 2014 by Eyal Toledano, Eyal Gura, and Elad Benjamin and funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, and Dolby Ventures. Zebra Medical Vision has raised $52 million in funding to date, and was named a Fast Company Top-5 AI and Machine Learning company.


Company Media Contact:

Alona Stein

Blonde 2.0 for Zebra Medical Vision

Intelerad Media Contact: Julie Perrone

External Communications Manager

(514) 931-6222 x 6423

error: Content is protected !!